-
FDA Accepts Biologics License Application for Denosumab Biosimilar Candidate
06 Jun 2024 15:02 GMT
The FDA accepted a biologics license application for a denosumab (Prolia; Amgen) … osteoporosis.3 The trial was a randomized, … the results.3
Treatment was randomized and … Furthermore, certain medications, including cancer medication and glucocorticoid steroids …
-
3 Biotech Stocks With Potential Breakthroughs Emerging
03 Jun 2024 22:48 GMT
… buying fundamentally strong biotech stocks: Amgen Inc. (AMGN), … and developing innovative vaccines and therapies. The … drug development, support the growing demand for personalized medicines … enhancing its liver disease treatment portfolio with CymaBay’s …
-
Sandoz receives European Commission approval for Wyost and Jubbonti, biosimilars of denosumab
31 May 2024 15:20 GMT
… (denosumab), the first and only biosimilar versions of reference medicines Xgeva® and Prolia … ® in Europe.
Wyost® is approved for the treatment … approval of the first European denosumab biosimilars is a crucial recognition …
-
15 Most Profitable Biotechnology Companies in the World
31 May 2024 16:41 GMT
… usage in drug discovery, personalized medicine, agriculture biotechnology, and … immune thrombocytopenia. Their vaccine sales grew 5. … and increase clinical trial diversity by 2025. … Prolia (denosumab) and XGEVA (denosumab) are Amgen’s innovative treatments for …
-
Samsung Bioepis Announces Oral Presentation on Switching Period Results for SB16, a Proposed Biosimilar to Prolia (Denosumab) at the European Calcified Tissue Society (ECTS) Congress 2024
27 May 2024 08:00 GMT
… SB16 comparable with reference denosumab before and after … 18 was comparable between treatment groups. The least squares … SB16 (Proposed Denosumab Biosimilar) to Reference Denosumab in Patients … LinkedIn. 1 Prolia is a trademark of Amgen.
MEDIA CONTACT
Anna …
-
EMA validates MAA for Prolia and Xgeva (denosumab) biosimilar candidate HLX14
27 May 2024 11:53 GMT
… Prolia and Xgeva (denosumab). This announcement was made by Shanghai Henlius Biotech … as for osteoporosis treatment in postmenopausal women … Phase III clinical trial. This international, randomised … franchise of established medicines across various therapeutic …
-
EMA validates Henlius & Organon's marketing authorization applications for Prolia and Xgeva biosimilar
27 May 2024 11:10 GMT
Shanghai Henlius Biotech, Inc., a global … an investigational Prolia and Xgeva (denosumab) biosimilar. Denosumab has been approved … such as for the treatment of osteoporosis in … affordable, and innovative biologic medicines for patients worldwide with …
-
La Agencia Europa de Medicamentos (EMA) ha validado las solicitudes de Henlius y Organon para el candidato a biosimilar HLX14 de Prolia ® y Xgeva ® (denosumab)
26 May 2024 16:55 GMT
… )--may. 26, 2024--
Shanghai Henlius Biotech, Inc. (2696.HK) y Organon … que la Agencia Europa de Medicamentos (EMA) ha validado las solicitudes … fase de investigación de Prolia ® y Xgeva ® (denosumab). Denosumab está aprobado en varios …
-
L’Agence européenne des médicaments (EMA) entérine les dépôts de Henlius et d’Organon pour le candidat biosimilaire HLX14 de Prolia ® et Xgeva ® (denosumab)
24 May 2024 18:53 GMT
… )--mai 24, 2024--
Shanghai Henlius Biotech, Inc. (2696.HK) et Organon … que l’Agence européenne des médicaments (EMA) a validé les demandes … biosimilaire expérimental de Prolia ® et Xgeva ®. Le denosumab a déjà été approuvé …
-
Europäische Arzneimittel-Agentur (EMA) validiert Einreichungen von Henlius und Organon für den Prolia ® und Xgeva ® (Denosumab) Biosimilar-Kandidaten HLX14
24 May 2024 18:53 GMT
… )--Mai 24, 2024--
Shanghai Henlius Biotech, Inc. (2696.HK) und Organon … HLX14, einen Prolia ® und Xgeva ® (Denosumab) Biosimilar-Kandidaten validiert hat. Denosumab ist in …